#########
Volume 10, Number 50
Monday, December 20, 2010
#########



In this issue: (click heading to view article)
#########
######### From the Editor: Got to Love Those Boomers
#########
######### Prevalence and Risk Factors for Cataract in Diabetes
#########
######### Visual Field Loss in Glaucoma and Health-Related Quality of Life
#########
######### Changes in Peripapillary Retinal Blood Flow in Patients with Disc Hemorrhages
#########
######### Ocular Complications in Lung Transplant Patients
#########
######### Briefly





http://www.haag-streit-brands.com/products/imbq/







From the Editor: Got to Love Those Boomers


Recently, during a visit by my practice development consultant, we got on the subject of Baby Boomers and the impact they will have on health care in America. When I was a resident back in the mid-1980s, the Baby Boomers were in their 30 and 40s. Now, they are crashing the gates of Social Security and Medicare. I once read a funny description of a Boomer as an individual who completely expects all in return from the government in terms of benefits they contributed to during working years as they zip all around Tuscany. Honestly, that pretty much sums up my wife and me.

Realistically speaking, this country has a big problem on its hands. As physicians, we realize this. We are trained to face facts, be honest and be realistic. This could be quite sobering. Presently, there about 50 million Americans aged 65 or older. By 2025, that number will balloon to 83 million. Last I looked, there are no specific plans to train more physicians, and how are we going to foot the bill for all this health care? Keep in mind, these are not the “Brokaw generation” that was more accepting of the limitations of health care. Boomers are highly educated, thanks to the Internet, and they expect more from health care.

Physicians MUST play an active roll as we move forward in crafting solutions through this process. We cannot be viewed as the cause of the rising cost of health care, but more so as part of the solution. If we do not, then the consequences of decisions that may be made to cope with this issue may stress the medical profession to the breaking point.

Stephen Pascucci, MD, FACS














Prevalence and Risk Factors for Cataract in Diabetes

To report the prevalence of cataract and its subtypes in patients with type 2 diabetes mellitus and the risk factors associated with these cataracts, researchers in India enrolled 1,283 eligible subjects with type 2 diabetes mellitus from a cross-sectional study. These patients underwent examination and a trained ophthalmologist graded lens opacity according to the Lens Opacity Classification System (LOCS) III system.

The researchers reported that the age- and sex-adjusted prevalence of cataract in the study was 65.7% (95% confidence interval [CI], 65.6–65.8) and that mixed cataracts were more common than monotype ones (41.6% vs. 19.4%). They also noted that the prevalence of cataract was higher in women, subjects with known diabetes and those with longer duration of diabetes (51.4%, 50.3% and 64.5%, respectively). The risk factors for any type of cataract were increasing age (odds ratio [OR], 1.14; 95% CI, 1.11–1.16), macroalbuminuria (OR, 4.61; 95% CI, 1.56–13.59) and increasing glycosylated hemoglobin (OR, 1.92; 95% CI, 1.22–3.00); higher hemoglobin (OR, 0.38; 95% CI, 0.22–0.64) was the protective factor.

The risk factors for nuclear cataract included increasing age (OR, 1.15) and high serum triglycerides (OR, 6.83). For cortical cataract, increasing age (OR, 1.14) and poor glycemic control (OR, 2.43) were the risk factors; increasing hemoglobin (OR, 0.14) was the protective factor. The study researchers found that for posterior subcapsular cataract, the risk factors included increasing age (OR, 1.11), being of the female sex (OR, 9.12), employment (OR, 9.80) and duration of diabetes (OR, 21.37).

They determined that nearly two-thirds of the diabetic population showed evidence of cataract; mixed cataracts were more common than the monotypes ones.

SOURCE: Raman R, Pal SS, Adams JS, et al. Prevalence and risk factors for cataract in diabetes: Sankara Nethralaya Diabetic Retinopathy Epidemiology and Molecular Genetics Study, Report No. 17. Invest Ophthalmol Vis Sci 2010;51(12):6253–6261.









Visual Field Loss in Glaucoma and Health-Related Quality of Life

In the Netherlands, a cross-sectional study including 537 ocular hypertension (OHT) and primary open-angle glaucoma (POAG) patients from seven hospitals investigated the relationship between visual field loss and health-related quality-of-life (HRQOL) in patients with both of these conditions.

Clinical information was obtained from medical files and patients completed a questionnaire, containing generic HRQOL instruments (EQ-5D and Health Utilities Index mark 3), vision-specific National Eye Institute Visual Functioning Questionnaire (VFQ-25) and glaucoma-specific Glaucoma Quality-of-Life questionnaire (GQL-15). The impact of visual field loss on HRQOL scores was analyzed with multiple linear regression analyses.

A relationship between mean deviation (MD) and HRQOL was found after adjusting for age, gender, visual acuity, medication side effects, laser trabeculoplasty and glaucoma surgery. Interaction was also found between MD in both eyes for GQL and VFQ-25 scores. It was reported that the relationship between MD and utility was non-linear, with utility only affected at MD-values below –25 dB in the better eye and that visual acuity, side effects and glaucoma surgery independently affected HRQOL. Binocular MD and MD in the better eye had similar impacts on HRQOL, whereas MD in the worse eye had an independent effect. HRQOL was affected more by binocular defects in the inferior than in the superior hemifield.

It was concluded that visual field loss in progressing glaucoma is independently associated with a loss in both disease-specific and generic quality-of-life. It is important to prevent progression, both in early and in advanced glaucoma, especially in patients with inferior hemifield defects and severe defects in either eye.


SOURCE: van Gestel A, Webers CA, Beckers HJ, et al. The relationship between visual field loss in glaucoma and health-related quality-of-life. Eye 2010;24(12):1759–1769.







Changes in Peripapillary Retinal Blood Flow in Patients with Disc Hemorrhages

The authors of this study investigated whether any peripapillary retinal blood flow changes are related to disc hemorrhage (DH).

They included 21 eyes of 21 patients, of which 14 eyes had glaucoma and examined all eyes at the time of detection of DH and again 6 months later. The authors measured blood flow in the peripapillary retina by scanning laser Doppler flowmetry and obtained four adjacent images focused on the peripapillary nerve fiber layer. They calculated retinal perfusion in arbitrary units by automatic full-field perfusion image analysis. The mean of all four rectangles representing the whole temporal peripapillary retina plus the rectangle representing the area of DH served for analysis.

According to the authors, the mean of measurements in all four areas revealed a statistically significant increase in mean flow (MF), systolic flow (SF) and diastolic flow (DF) and a decrease in pulsation index (PI). They found that the rectangle representing the area of DH showed a significant increase in MF, but the SF increase was of borderline significance. Changes in DF and PI did not reach statistical significance.

The results of the study indicate reduced flow at the time of DH and increased flow after resorption.

SOURCE: Kurvinen L, Harju M, Saari J, Vesti E. Altered temporal peripapillary retinal flow in patients with disc hemorrhages. Graefes Arch Clin Exp Ophthalmol 2010;248(12):1771–1775.









Ocular Complications in Lung Transplant Patients

To describe infectious and non-infectious ocular complications found in patients with lung transplants, investigators included patients who underwent ophthalmic examination at the Cole Eye Institute after lung transplantation from January 1998 to September 2008.

The investigators examined diagnoses, treatments, surgeries, laboratory parameters of immune status and patient survival. Of the 545 patients who received a lung transplant during the study period at the Cleveland Clinic, 46 (8.4%) patients underwent ophthalmology examination after a lung transplant. The most common ocular finding noted by the investigators was posterior subcapsular cataract, found in 13/46 (28.3%) patients. Infectious ocular complications were present in 6/46 patients (13.0%) including fungal infections (rhino-orbital mucormycosis [n=1], disseminated Pseudallescheria boydii infection [n=2]), cytomegalovirus retinitis (n=1), varicella-zoster virus keratouveitis (n=1) and herpes zoster ophthalmicus (n=1). The investigators reported that five of six patients with infectious complications died within 6 months of evaluation and associated decreased absolute lymphocyte count with infectious ocular complications (p=0.014).

In conclusion, many ocular conditions can occur in patients with lung transplants. The investigators determined that ocular infectious complications were uncommon but may be associated with increased mortality.

SOURCE: Tarabishy AB, Khatib OF, Nocero JR, et al. Ocular complications in patients with lung transplants. Br J Ophthalmol 2010;Dec 3 [Epub ahead of print].





  • ALCON-NOVARTIS MERGER OFFERS EXPANDED OPPORTUNITIES. In a recent press release, Alcon, Inc. announced that its board of directors approved a merger agreement with Novartis AG, whereby Novartis will pay a total merger consideration valued at $168 per share for the Alcon shares it does not currently own.

    The merger, which is expected to be completed during the first half of 2011, will be effected under Swiss merger law and is conditional, among other things, on two-thirds approval by the shareholders of both Novartis and Alcon voting at their respective meetings. Upon completion of the merger, Alcon will become the second largest division within Novartis. CIBA VISION and select Novartis ophthalmic medicines will be integrated into Alcon, forming an organization with more than $8.7 billion in sales covering more than 70% of the eye care segment. According to Alcon, the new eye care division will combine the company's in-depth scientific knowledge of eye disease and clinical experience with the broad-based research capabilities and resources of Novartis, allowing for an expanded commitment to research and development activities in eye care.
  • ACADEMY COLLABORATES ON IPHONE APP. The American Academy of Ophthalmology has collaborated with Cloud Nine Development, LLC, to enhance its iPhone application, the Eye Handbook, which is available for free on iTunes. The application, created for ophthalmologists by ophthalmologists, offers ophthalmic calculators, clinical videos, study tools and more and through the partnership, now features select Academy Summary Benchmarks for Preferred Practice Pattern Guidelines, patient education videos and a link to the Academy's latest online clinical offering, the EyeWiki. Visit www.eyehandbook.com to learn more.
  • NEW COMPACT GONIO LENS FROM VOLK. Now available is Volk Optical's new Mini 4 Mirror Gonio Lens, which, according to Volk, delivers complete angle views. The Mini 4 Mirror offers a full view of the chamber angle at 1.0x magnification with a slight lens rotation and the small body and ring make for easy manipulation of the lens, especially within a small orbit. The company says that its newest lens is an excellent complement to a standard 4 mirror Gonio lens, offering additional flexibility with a smaller body. For more information, visit www.volk.com.
  • PHASE 2 STUDY EXAMINES NEW INDICATION FOR BEPOTASTINE BESILATE. ISTA Pharmaceuticals, Inc. has initiated a Phase 2 clinical study of bepotastine besilate nasal spray for the treatment of symptoms associated with seasonal allergic rhinitis. The randomized, placebo-controlled, parallel-group environmental study will evaluate the safety and efficacy of the drug, dosed twice daily, in patients presenting with allergic rhinitis caused by a potent seasonal allergy trigger, Mountain Cedar pollen. ISTA currently offers Bepreve (bepotastine besilate ophthalmic solution) 1.5% for the treatment of ocular itching associated with allergic conjunctivitis. Preliminary data from this current study are expected in the first half of 2011. To read more, click here.